Context Elevated nonfasting triglycerides indicate the presence of remnant lipoproteins, which may promote atherosclerosis.
Objective To test the hypothesis that very high levels of nonfasting triglycerides predict myocardial infarction (MI), ischemic heart disease (IHD), and death.
Design, Setting, and Participants A prospective cohort study of 7587 women and 6394 men from the general population of Copenhagen, Denmark, aged 20 to 93 years, followed up from baseline (1976-1978) until 2004.
Main Outcome Measures Hazard ratios (HRs) for incident MI, IHD, and total death according to baseline nonfasting triglyceride level categories of 1 to 1.99 mmol/L (88.5-176.1 mg/dL), 2 to 2.99 mmol/L (177.0-264.6 mg/dL), 3 to 3.99 mmol/L (265.5-353.0 mg/dL), 4 to 4.99 mmol/L (354.0-441.6 mg/dL), and 5 mmol/L or more (≥442.5 mg/dL) vs triglyceride levels of less than 1 mmol/L (<88.5 mg/dL).
Results With increasing levels of nonfasting triglycerides, levels of remnant lipoprotein cholesterol increased. During a mean follow-up of 26 years, 1793 participants (691 women and 1102 men) developed MI, 3479 (1567 women and 1912 men) developed IHD, and 7818 (3731 women and 4087 men) died. For MI, among women, the age-adjusted HRs and multifactorially adjusted HRs (aHRs) for each respective category per 1-mmol/L increase in nonfasting triglyceride levels were 2.2 (aHR, 1.7), 4.4 (aHR, 2.5), 3.9 (aHR, 2.1), 5.1 (aHR, 2.4), and 16.8 (aHR, 5.4); for both, P for trend < .001. For MI, among men, the values were 1.6 (aHR, 1.4), 2.3 (aHR, 1.6), 3.6 (aHR, 2.3), 3.3 (aHR, 1.9), and 4.6 (aHR, 2.4); for both, P for trend < .001. For IHD, among women, the values were 1.7 (aHR, 1.4), 2.8 (aHR, 1.8), 3.0 (aHR, 1.8), 2.1 (aHR, 1.2), and 5.9 (aHR, 2.6); for both, P for trend < .001. For IHD, among men, the values were 1.3 (aHR, 1.1), 1.7 (aHR, 1.3), 2.1 (aHR, 1.3), 2.0 (aHR, 1.2), and 2.9 (aHR, 1.5); P for trend < .001 for age-adjusted and P for trend = .03 for multifactorially adjusted. For total death, among women, the values were 1.3 (aHR, 1.3), 1.7 (aHR, 1.6), 2.2 (aHR, 2.2), 2.2 (aHR, 1.9), and 4.3 (aHR, 3.3); for both, P for trend < .001. For total death, among men, the values were 1.3 (aHR, 1.2), 1.4 (aHR, 1.4), 1.7 (aHR, 1.5), 1.8 (aHR, 1.6), and 2.0 (aHR, 1.8); for both, P for trend < .001.
Conclusion In this general population cohort, elevated nonfasting triglyceride levels were associated with increased risk of MI, IHD, and death in men and women.
Hypertriglyceridemia is a heterogeneous disorder with an unclear association with atherosclerosis.1-4 Patients with high triglyceride levels of more than 25 mmol/L (>2212.4 mg/dL) and the familial chylomicronemia syndrome rarely develop atherosclerosis,4 perhaps because their plasma lipoprotein particles are too large to enter into the arterial intima.5,6 However, patients with moderate hypertriglyceridemia and conditions like familial hypertriglyceridemia, familial combined hyperlipidemia, the metabolic syndrome, and remnant hyperlipidemia often develop premature atherosclerosis.1-4 With moderate hypertriglyceridemia, chylomicron remnants and very low-density lipoprotein remnants are present in plasma. These smaller triglyceride-rich lipoproteins penetrate the arterial intima7 and appear to be preferentially trapped within the arterial wall.8,9
Triglycerides are routinely measured in the fasting state excluding remnant lipoproteins; however, except for the first hours in the early morning, most individuals are in the nonfasting state most of the time. Atherosclerosis may be a postprandial phenomenon in which remnant lipoproteins play a dominant role.10-12 If this is true, increased levels of nonfasting triglycerides, reflecting increased levels of remnant lipoproteins, may predict risk of myocardial infarction (MI), ischemic heart disease (IHD), and death.
We tested the hypothesis that nonfasting triglycerides predict risk of MI, IHD, and death in the general population. We studied 7587 women and 6394 men from the Copenhagen City Heart Study cohort who were followed up for a mean of 26 years (maximum follow-up, 28 years).
The Copenhagen City Heart Study is a prospective cardiovascular study of the Danish general population initiated in 1976.13 We invited 19 329 white women and men of Danish descent stratified into 5-year age groups from 20 years to 80 years or older, and drawn randomly from the Copenhagen Central Person Register. Of those participants invited, 14 223 (74%) attended and 13 981 (72%) had nonfasting triglyceride levels determined on fresh plasma samples. Participants were followed up using their unique Central Person Register number from baseline at the 1976-1978 examination until the beginning of 2004. Follow-up was 100% complete.
Diagnoses of MI and IHD (International Classification of Diseases, Eighth Revision codes 410 and 410-414; and International Classification of Diseases, Tenth Revision codes I21-I22 and I20-I25) were collected and verified by reviewing hospital admissions and diagnoses entered in the Danish National Patient Register, causes of death entered in the Danish National Register of Causes of Death, and medical records from hospitals and general practitioners. Ischemic heart disease was determined on the basis of a previous MI or characteristic symptoms of stable or unstable angina pectoris14; time to IHD was determined from the date of study entry until the first date of a diagnosis of either MI or angina pectoris. A diagnosis of MI required the presence of at least 2 of the following criteria: characteristic chest pain, increased cardiac enzymes, or electrocardiographic changes indicative of MI. Information on death was obtained from the Danish National Central Person Register.
Hypertension was defined as use of antihypertensive medication, a systolic blood pressure of more than 140 mm Hg, or a diastolic blood pressure of more than 90 mm Hg. Diabetes mellitus was defined as self-reported disease, use of insulin or oral hypoglycemic agents, or nonfasting plasma glucose levels of more than 198.2 mg/dL (>11 mmol/L). Smokers were defined as active smokers. Heavy drinkers consumed alcohol at least twice weekly, while light drinkers consumed alcohol less often. Physical inactivity was defined as leisure time activity less than 4 hours weekly. Women reported menopausal status and use of hormone therapy. We did not have information on food consumed during the 8 hours before blood testing.
A fat tolerance test was performed on 66 healthy participants from the Copenhagen City Heart Study aged 46 to 88 years.15 In another study population of 10 284 participants aged 20 to 90 years, the Copenhagen General Population Study ascertained like the Copenhagen City Heart Study, but in 2003 through 2005, we also measured nonfasting triglyceride levels. We measured 1 triglyceride value in each participant and noted the amount of time that had elapsed since their last meal. Data from this study have never previously been published.
The studies were approved by Herlev University Hospital and a Danish ethical committee (100.2039/91 and 01-144/01, Copenhagen and Frederiksberg committee) and conducted according to the Declaration of Helsinki. Participants gave written informed consent.
Enzymatic methods (Boehringer Mannheim, Mannheim, Germany) were used on fresh samples to measure plasma levels of nonfasting triglycerides, total cholesterol, and high-density lipoprotein (HDL) cholesterol, the latter after precipitation of apolipoprotein B–containing lipoproteins. The coefficient of variation for measurement of triglycerides at the levels of 1.0 and 3.2 mmol/L (88.5 and 283.2 mg/dL) were 5% and 2%, respectively. Remnant lipoprotein cholesterol was total cholesterol minus cholesterol in HDLs and low-density lipoproteins (LDLs). Low-density lipoprotein was calculated using the Friedewald formula if triglycerides were less than 4 mmol/L (<354.0 mg/dL), and measured directly at higher triglyceride levels (Thermo, Helsinki, Finland).
Statistical analyses were stratified by sex. t Test or Pearson χ2 test was used in 2-group comparisons; plasma triglycerides were logarithmically transformed to approach normal distribution. Baseline nonfasting triglyceride levels were stratified into 6 categories (<1 mmol/L [<88.5 mg/dL], 1-1.99 mmol/L [88.5-176.1 mg/dL], 2-2.99 mmol/L [177.0-264.6 mg/dL], 3-3.99 mmol/L [265.5-353.1 mg/dL], 4-4.99 mmol/L [354.0-441.6 mg/dL], and ≥5 mmol/L [≥442.5 mg/dL]). To examine the effect of very high levels of nonfasting triglycerides vs low levels, we preplanned stratification cutoffs at each increase in 1 mmol/L (88.5 mg/dL) until the top group became too small for statistically meaningful comparison with the bottom group (<1 mmol/L [<88.5 mg/dL]).
Cumulative incidences were plotted using Kaplan-Meier curves and differences between strata of nonfasting triglyceride levels determined using log-rank tests. Cox proportional hazards regression models estimated hazard ratios (HRs) for MI, IHD, and death. Proportionality of hazards over time for nonfasting triglyceride levels was assessed by plotting –ln[–ln(survival)] vs ln(analysis time). Suspicion of nonparallel lines was further tested using Schoenfeld residuals. No major violations of the proportional hazard assumption were detected. For triglyceride levels between 2 and 2.99 mmol/L (177.0 and 264.6 mg/dL) and between 3 and 3.99 mmol/L (265.5 and 353.1 mg/dL) and total mortality in women, the proportional hazards assumption was not fulfilled; however, the assumption was fulfilled for the other triglyceride categories in this model. For all survival statistics, age was the time scale using left truncation (or delayed entry), which implies that age is automatically adjusted for.
Hazard ratios were adjusted for age alone (age-adjusted), or for age and other cardiovascular risk factors (multifactorially adjusted for age, total cholesterol, body mass index, hypertension, diabetes, smoking, alcohol consumption, physical inactivity, lipid-lowering therapy, and in women also for postmenopausal status and hormone therapy). Information on baseline covariates was more than 99% complete; individuals with incomplete information on covariates were excluded from multifactorial analysis. Data from the 1976-1978, 1981-1983, 1991-1994, and 2001-2003 examinations were used as time-dependent covariates for multifactorial adjustments. This implies that initially baseline covariate values are used for the following years until that person is examined again, after which the new value is used in the analyses. If only baseline values were available, these were used for adjustment during the entire follow-up period.
Hazard ratios were corrected for regression dilution bias using a nonparametric method.16 For this correction, we used nonfasting triglyceride values from 6709 individuals without lipid-lowering therapy attending both the baseline 1976-1978 examination and the 1991-1994 examination (available from authors upon request); however, the main analyses were conducted on 13 981 individuals. These 2 measurements were 15 years apart, equivalent to halfway through the observational period, the ideal time difference for this correction.16 A regression dilution ratio of 0.57 was computed for women and a regression dilution ratio of 0.60 was computed for men.
Due to the complete Danish registers, we had no losses to follow-up among responders or nonresponders. Data were analyzed using Stata version 9.2 (StataCorp LP, College Station, Texas). Two-sided P<.05 was considered significant.
Baseline characteristics of individuals from the general population by quartiles of nonfasting triglyceride levels are shown in Table 1. At the 1976-1978 (baseline), 1981-1983, 1991-1994, and 2001-2003 examinations, 0%, 0%, 1%, and 2%, respectively, of the participants took lipid-lowering drugs. The study included 13 981 individuals (7587 women and 6394 men) aged 20 to 93 years, with mean 26 years of follow-up. A total of 1793 (691 women and 1102 men) developed MI, 3479 (1567 women and 1912 men) developed IHD, and 7818 (3731 women and 4087 men) died.
Nonfasting Triglycerides and Remnant Lipoprotein Cholesterol
In a cross-sectional sample of the Danish general population of 10 284 adults from the Copenhagen General Population Study, the plasma triglyceride levels were noted to be increased among participants who had eaten their most recent meal from 1 to 7 hours previously (Figure 1). The measured levels of nonfasting triglycerides after normal food intake marked increased levels of cholesterol in remnant lipoproteins. During a fat tolerance test, plasma triglyceride levels reached a mean peak level of 2.3 mmol/L (203.5 mg/dL) 4 hours after fat intake, whereas in individuals from the general population the mean peak level was 1.6 mmol/L (61.8 mg/dL) 4 hours after normal food intake. Triglyceride levels normally return to baseline fasting levels at 10 hours after the fat meal17; however, we only had data for 6 hours after the fat meal.
With increasing levels of nonfasting triglycerides, levels of remnant lipoprotein cholesterol increased (Figure 2). These levels were measured in 6677 of the original participants from the Copenhagen City Heart Study, who also had nonfasting triglycerides and remnant lipoprotein cholesterol measured at the 1991-1994 examination.
In men and women, the cumulative incidence of MI, IHD, and death increased with increasing levels of nonfasting triglyceride levels (all log-rank trend tests, P < .001) (Figure 3).
For MI, the incidence rates in women in events per 10 000 person-years were 21 (95% confidence interval [CI], 18-26; 109 events) for nonfasting triglyceride level categories of less than 1 mmol/L (<88.5 mg/dL), 46 (95% CI, 42-51; 382 events) for 1 to 1.99 mmol/L (88.5-176.1 mg/dL), 77 (95% CI, 65-91; 141 events) for 2 to 2.99 mmol/L (177.0-264.6 mg/dL), 71 (95% CI, 49-101; 30 events) for 3 to 3.99 mmol/L (265.5-353.0 mg/dL), 77 (95% CI, 46-130; 14 events) for 4 to 4.99 mmol/L (354.0-441.6 mg/dL), and 152 (95% CI, 92-252; 15 events) for 5 mmol/L or more (≥442.5 mg/dL). The corresponding incidence rates in men in events per 10 000 person-years were 60 (95% CI, 49-73; 104 events), 90 (95% CI, 82-98; 477 events), 114 (95% CI, 101-128; 270 events), 143 (95% CI, 120-169; 133 events), 137 (95% CI, 105-178; 54 events), and 150 (95% CI, 117-192; 64 events), respectively.
For MI, women with increased nonfasting triglyceride levels had age-adjusted HRs of 2.2 (95% CI, 1.6-3.2) for triglyceride levels of 1 to 1.99 mmol/L (88.5-176.1 mg/dL), 4.4 (95% CI, 2.9-6.8) for 2 to 2.99 mmol/L (177.0-264.6 mg/dL), 3.9 (95% CI, 2.0-7.7) for 3 to 3.99 mmol/L (265.5-353.0 mg/dL), 5.1 (95% CI, 2.0-12.9) for 4 to 4.99 mmol/L (354.0-441.6 mg/dL), and 16.8 (95% CI, 6.8-41.6) for 5 mmol/L or more (≥442.5 mg/dL) vs women with nonfasting triglyceride levels of less than 1 mmol/L (<88.5 mg/dL) (Figure 4). The corresponding values for men were 1.6 (95% CI, 1.1-2.3), 2.3 (95% CI, 1.5-3.4), 3.6 (95% CI, 2.3-5.7), 3.3 (95% CI, 1.9-5.9), and 4.6 (95% CI, 2.7-8.0), respectively.
For IHD, the incidence rates in women in events per 10 000 person-years were 58 (95% CI, 51-65; 290 events), 109 (95% CI, 102-117; 878 events), 163 (95% CI, 145-183; 289 events), 164 (95% CI, 129-209; 66 events), 130 (95% CI, 86-195; 23 events), and 223 (95% CI, 146-342; 21 events), respectively, for the 6 nonfasting triglyceride level categories. The corresponding incidence rates in men in events per 10 000 person-years were 126 (95% CI, 110-144; 214 events), 167 (95% CI, 156-178; 853 events), 205 (95% CI, 188-225; 469 events), 220 (95% CI, 191-252; 198 events), 211 (95% CI, 170-263; 80 events), and 238 (95% CI, 195-290; 98 events), respectively.
For IHD, women with increased nonfasting triglyceride levels had age-adjusted HRs of 1.7 (95% CI, 1.4-2.1), 2.8 (95% CI, 2.1-3.6), 3.0 (95% CI, 1.9-4.7), 2.1 (95% CI, 1.0-4.3), and 5.9 (95% CI, 2.8-12.4), respectively, for the 5 nonfasting triglyceride level categories vs women with nonfasting triglyceride levels of less than 1 mmol/L (<88.5 mg/dL) (Figure 4). The corresponding values in men were 1.3 (95% CI, 1.0-1.7), 1.7 (95% CI, 1.3-2.3), 2.1 (95% CI, 1.5-3.0), 2.0 (95% CI, 1.2-3.1), and 2.9 (95% CI, 1.9-4.5), respectively.
For total death, the incidence rates in women in events per 10 000 person-years were 145 (95% CI, 135-156; 754 events), 245 (95% CI, 235-256; 2076 events), 325 (95% CI, 300-351; 623 events), 373 (95% CI, 320-435; 164 events), 345 (95% CI, 270-441; 64 events), and 469 (95% CI, 356-619; 50 events), respectively, for the 6 nonfasting triglyceride level categories. The corresponding incidence rates in men in events per 10 000 person-years were 260 (95% CI, 238-285; 470 events), 345 (95% CI, 330-360; 1920 events), 380 (95% CI, 356-405; 959 events), 384 (95% CI, 348-424; 386 events), 412 (95% CI, 355-477; 176 events), and 377 (95% CI, 325-436; 176 events), respectively.
For total death, women with increased nonfasting triglyceride levels had age-adjusted HRs of 1.3 (95% CI, 1.2-1.5), 1.7 (95% CI, 1.5-2.1), 2.2 (95% CI, 1.7-3.0), 2.2 (95% CI, 1.4-3.4), and 4.3 (95% CI, 2.7-7.0), respectively, for the 5 nonfasting triglyceride level categories vs women with nonfasting triglyceride levels of less than 1 mmol/L (<88.5 mg/dL) (Figure 4). The corresponding values in men were 1.3 (95% CI, 1.1-1.5), 1.4 (95% CI, 1.2-1.7), 1.7 (95% CI, 1.3-2.1), 1.8 (95% CI, 1.3-2.4), and 2.0 (95% CI, 1.5-2.8), respectively.
Hazard ratios for risk of MI, IHD, and death were attenuated after multifactorial adjustment (Figure 4). For MI in women, the multifactorially adjusted HRs were 1.7 (95% CI, 1.2-2.5), 2.5 (95% CI, 1.6-3.9), 2.1 (95% CI, 1.0-4.3), 2.4 (95% CI, 0.9-6.2), and 5.4 (95% CI, 2.1-13.9), respectively, for the 5 nonfasting triglyceride level categories vs triglyceride levels of less than 1 mmol/L (<88.5 mg/dL). The corresponding values in men were 1.4 (95% CI, 1.0-2.1), 1.6 (95% CI, 1.1-2.4), 2.3 (95% CI, 1.4-3.7), 1.9 (95% CI, 1.0-3.4), and 2.4 (95% CI, 1.3-4.2), respectively. For IHD in women, the multifactorially adjusted HRs were 1.4 (95% CI, 1.1-1.8), 1.8 (95% CI, 1.4-2.5), 1.8 (95% CI, 1.2-2.9), 1.2 (95% CI, 0.6-2.5), and 2.6 (95% CI, 1.2-5.5), respectively, for the 5 nonfasting triglyceride level categories vs triglyceride levels of less than 1 mmol/L (<88.5 mg/dL). The corresponding values in men were 1.1 (95% CI, 0.8-1.4), 1.3 (95% CI, 0.9-1.7), 1.3 (95% CI, 0.9-1.9), 1.2 (95% CI, 0.7-1.9), and 1.5 (95% CI, 1.0-2.4), respectively. For death in women, the multifactorially adjusted HRs were 1.3 (95% CI, 1.1-1.5), 1.6 (95% CI, 1.4-2.0), 2.2 (95% CI, 1.7-3.0), 1.9 (95% CI, 1.2-3.0), and 3.3 (95% CI, 2.0-5.4), respectively, for the 5 nonfasting triglyceride level categories vs triglyceride levels of less than 1 mmol/L (<88.5 mg/dL). The corresponding values in men were 1.2 (95% CI, 1.0-1.5), 1.4 (95% CI, 1.1-1.7), 1.5 (95% CI, 1.2-2.0), 1.6 (95% CI, 1.1-2.1), and 1.8 (95% CI, 1.3-2.5), respectively.
In post hoc analyses in men, age-adjusted HRs were more pronounced in those individuals with entry age of 55 years or younger vs older than 55 years, and in light vs heavy alcohol drinkers (Figure 5).
Nonfasting Triglyceride Levels on a Continuous Scale
When considered as a continuous variable, nonfasting triglyceride levels were independently predictive of MI and death in women and of death in men (Table 2).
We found that elevated nonfasting triglyceride levels, which indicate the presence of remnant lipoproteins, were associated with increased risk of MI, IHD, and total death in men and women in the general population. Because most previous studies18-20 have focused on fasting levels of triglycerides that exclude remnant lipoproteins, and studied mainly tertiles or quartiles of triglycerides rather than very high levels, the demonstrated predictive ability of nonfasting triglyceride levels of 5 mmol/L or more (≥442.5 mg/dL) has previously gone unnoticed. In our data, there even appears in some cases to be a “jump” in HRs between triglyceride levels of less than 5 mmol/L and triglyceride levels of 5 mmol/L or more. It is not triglycerides per se that cause atherosclerosis but rather the cholesterol content of remnant lipoproteins. This finding is apparent from comparing the age-adjusted HRs with the multifactorially adjusted HRs; multifactorial adjustment masks the effect of triglycerides by adjusting for factors like overweight and diabetes, which are known to lead to elevated levels of triglycerides and remnant lipoproteins.
Increased levels of nonfasting triglycerides may indicate the presence of increased levels of atherogenic remnant lipoproteins.10 Because all human cells can degrade triglycerides but not cholesterol, and because remnant lipoproteins like LDL carry large amounts of cholesterol, it is the cholesterol content of remnant particles that upon entrance into the arterial intima can cause atherosclerosis.10,12 Like LDLs, remnant lipoproteins can enter into the arterial intima7 and may even be trapped preferentially within the arterial wall.8 Patients with genetic disorders leading to large amounts of plasma remnant lipoproteins develop premature atherosclerosis2 and patients with familial hypertriglyceridemia have increased risk of cardiovascular death.1 Also, heterozygosity for genetic defects in lipoprotein lipase, the plasma enzyme degrading triglycerides, associates with increased triglyceride levels as well as increased risk of IHD.4,21,22 Furthermore, patients with the familial chylomicronemia syndrome who during part of their life due to lipid-lowering treatment have triglyceride levels of 3 to 7 mmol/L (265.5-619.5 mg/dL) also develop premature atherosclerosis.23 Finally, subanalyses of 3 randomized double-blind trials suggest that among patients with increased triglyceride levels, a 20% to 40% reduction in triglyceride levels associates with a 30% to 40% reduction in risk of IHD.24-26
Our cross-sectional data (Figure 1) suggest that most people eat less fat during normal food intake than during a fat tolerance test, simply because individuals in the general population have less plasma triglycerides in response to normal food intake than during a fat tolerance test of 1-gram dairy cream per kilogram of body weight. The only modest increase in triglyceride levels during normal food intake together with our demonstration of high predictive ability of nonfasting triglycerides for risk of MI, IHD, and death opens the possibility that nonfasting rather than fasting triglyceride levels should be used for risk prediction. If implemented, this would simplify blood sampling for lipid measurements.
Increased triglyceride levels associate with reduced levels of HDL cholesterol, a strong risk factor for IHD.27 However, increased triglyceride levels is a risk factor for cardiovascular disease independent of HDL cholesterol levels.18 Because genetically reduced levels of HDL associate with decreased rather than increased risk of IHD,28 and vice versa for genetically increased levels of HDL cholesterol,29-31 HDL cholesterol levels per se may not directly influence development of atherosclerosis and IHD. Increased levels of triglycerides also associate with increased levels of small, dense LDLs, both of which associate with atherosclerosis.32 This association with atherosclerosis possibly can be explained by increased levels of remnant lipoproteins present in the nonfasting state rather than by small, dense LDL per se.33
Most previous studies on triglycerides have focused on fasting levels that exclude remnant lipoproteins, and most have only compared moderately increased vs low levels.18-20 Therefore, most previous studies cannot be compared directly with the results of our study. However, in accordance with our results, a Norwegian study found that nonfasting triglyceride levels of 3.5 mmol/L or more (≥309.7 mg/dL) vs less than 1.5 mmol/L (<132.7 mg/dL) was associated with a 5-fold risk of death from coronary heart disease and a 2-fold risk of total death in women.34 A recent meta-analysis found similar predictive ability for fasting and nonfasting upper vs lower tertiles of triglyceride levels on risk of coronary heart disease.20
In women, we observed better predictive ability of nonfasting triglyceride levels than in men, in accordance with similar findings for fasting triglyceride levels in some18,19 but not all previous meta-analyses.20 Our stratified analyses suggest that the predictive ability of nonfasting triglyceride levels for risk of MI, IHD, and death in young men who only consume small amounts of alcohol is similar to that in women. Therefore, because large alcohol intake often leads to increased triglyceride levels, and because these triglyceride-rich lipoproteins may differ from most remnant lipoproteins present in nonfasting plasma (type V vs type IIb hyperlipidemia), it is likely that high alcohol intake may have confounded the association between triglyceride levels and risk of MI, IHD, and death in men in this and former studies.
Our study limitations include that we only studied white participants, and therefore our results may not necessarily apply to other racial groups. Furthermore, the relatively small sample sizes and wide CIs in groups with the highest triglyceride levels are of concern. A few participants took lipid-lowering drugs late in the follow-up period, which could have confounded the results slightly; however, at the 1991-1994 and 2001-2003 examinations after the first 15 and 25 years of follow-up, only 1% and 2% of the participants took lipid-lowering drugs. When the analyses were adjusted for lipid-lowering drugs, the results changed only minimally. Nonfasting triglyceride level is dependent on the duration of fasting; however, since information on timing since the last meal was not available for participants of the Copenhagen City Heart Study examined in 1976-1978, this could not be taken into account in our analyses. Therefore, if triglyceride levels were measured at a fixed time point after a normal meal or even after a fat tolerance test, the predictive ability of nonfasting or postprandial triglyceride levels may be even better than that observed in our study for random nonfasting triglycerides.
Low participation rates may limit the ability to extend the results obtained to the population at large. However, we invited people at random to represent the general population, had a participation rate of 74%, and found incidences of MI and IHD, but not of total death, to be similar between responders and nonresponders. In addition, regression dilution bias may influence results,16 although we corrected for this bias. Furthermore, population admixture may bias results; however, 100% of our participants were white of Danish descent. Thus, our study strengths include an ethnically homogeneous large sample from a white general population with a very high participation rate, 26 years of 100% complete follow-up, and correction for regression dilution bias.
In this population, with 10 baseline dichotomized risk factors, smoking, hypertension, nonfasting hypercholesterolemia, obesity, physical inactivity, and diabetes in both sexes, nonfasting hypertriglyceridemia in women and no daily alcohol intake in men independently predicted increased risk of IHD.13 As levels of HDLs and LDLs were first measured at the 1991-1994 examination, these risk factors could not be evaluated during the entire period of follow-up; however, both these lipoproteins measured in the nonfasting state also predicted increased risk of IHD in the Copenhagen City Heart Study.35,36
We found that nonfasting triglyceride levels independently predict MI, IHD, and death, particularly in women. These findings may reflect the effects of remnant lipoproteins and therefore may be of considerable interest when designing future trials of agents aimed at reducing triglyceride levels or attenuating atherogenic metabolic abnormalities. If our findings are confirmed, clinical care might be simplified by using nonfasting lipid profiles for atherosclerosis risk prediction.
Corresponding Author: Børge G. Nordestgaard, MD, DMSc, Department of Clinical Biochemistry, Herlev University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark (brno@heh.regionh.dk).
Author Contributions: Drs Nordestgaard and Benn had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Nordestgaard, Benn, Schnohr.
Acquisition of data: Nordestgaard, Benn, Schnohr.
Analysis and interpretation of data: Nordestgaard, Benn, Tybjaerg-Hansen.
Drafting of the manuscript: Nordestgaard, Benn.
Critical revision of the manuscript for important intellectual content: Nordestgaard, Benn, Schnohr, Tybjaerg-Hansen.
Statistical analysis: Nordestgaard, Benn, Tybjaerg-Hansen.
Obtained funding: Nordestgaard, Schnohr, Tybjaerg-Hansen.
Administrative, technical, or material support: Nordestgaard, Schnohr.
Study supervision: Nordestgaard, Benn.
Financial Disclosures: Dr Nordestgaard reported being a consultant for Merck, Pfizer, BG Medicine, and AstraZeneca. No other authors reported any financial disclosures.
Funding/Support: This study was supported by The Danish Heart Foundation, The Danish Medical Research Council, The Research Fund at Rigshospitalet, Copenhagen University Hospital, and the European Union, Sixth Framework Programme Priority (FP-2005-LIFESCIHEALTH-6: contract 037631).
Role of the Sponsors: The study sponsors had no role in the conduct of the study, in the collection, management, analysis, or interpretation of data, or in the preparation, review, or approval of the manuscript.
Additional Contributions: We thank Jacob J. Freiberg, MD, Herlev University Hospital, for statistical assistance. Dr Freiberg did not receive any compensation for his contribution.
1.Austin MA, McKnight B, Edwards KL.
et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study.
Circulation. 2000;101(24):2777-278210859281
Google ScholarCrossref 2.Mahley RW, Rall SC. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:2835-2862
3.Sarti C, Gallagher J. The metabolic syndrome: prevalence, CHD risk, and treatment.
J Diabetes Complications. 2006;20(2):121-13216504841
Google ScholarCrossref 4.Brunzell JD, Deeb SS. Familial lipoprotein lipase deficiency, Apo C-II deficiency, and hepatic lipase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:2789-2816
5.Nordestgaard BG, Stender S, Kjeldsen K. Reduced atherogenesis in cholesterol-fed diabetic rabbits.
Arteriosclerosis. 1988;8(4):421-4283395278
Google ScholarCrossref 6.Nordestgaard BG, Zilversmit DB. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits.
J Lipid Res. 1988;29(11):1491-15003241125
Google Scholar 7.Shaikh M, Wootton R, Nordestgaard BG.
et al. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans.
Arterioscler Thromb. 1991;11(3):569-5772029497
Google ScholarCrossref 8.Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo: molecular size as a determinant of fractional loss from the intima-inner media.
Arterioscler Thromb Vasc Biol. 1995;15(4):534-5427749867
Google ScholarCrossref 9.Rutledge JC, Mullick AE, Gardner G, Goldberg IJ. Direct visualization of lipid deposition and reverse lipid transport in a perfused artery: roles of VLDL and HDL.
Circ Res. 2000;86(7):768-77310764410
Google ScholarCrossref 11.Patsch JR, Miesenbock G, Hopferwieser T.
et al. Relation of triglyceride metabolism and coronary artery disease.
Arterioscler Thromb. 1992;12(11):1336-13451420093
Google ScholarCrossref 12.Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS.
et al. Clinical relevance of postprandial lipaemia.
Curr Med Chem. 2005;12(17):1931-194516101498
Google ScholarCrossref 13.Schnohr P, Jensen JS, Scharling H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community: a 21-year follow-up of 12 000 men and women from the Copenhagen City Heart Study.
Eur Heart J. 2002;23((8)):620-62611969276
Google ScholarCrossref 14. Management of stable angina pectoris: recommendations of the Task Force of the European Society of Cardiology.
Eur Heart J. 1997;18(3):394-4139076376
Google ScholarCrossref 15.Kofoed SC, Gronholdt ML, Bismuth J.
et al. Echolucent, rupture-prone carotid plaques associated with elevated triglyceride-rich lipoproteins, particularly in women.
J Vasc Surg. 2002;36(4):783-79212368740
Google Scholar 16.Clarke R, Shipley M, Lewington S.
et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies.
Am J Epidemiol. 1999;150(4):341-35310453810
Google ScholarCrossref 17.Cohn JS, McNamara JR, Cohn SD.
et al. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal.
J Lipid Res. 1988;29(7):925-9363411251
Google Scholar 18.Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.
J Cardiovasc Risk. 1996;3(2):213-2198836866
Google ScholarCrossref 19.Austin MA. Plasma triglyceride and coronary heart disease.
Arterioscler Thromb. 1991;11(1):2-141987999
Google ScholarCrossref 20.Sarwar N, Danesh J, Eiriksdottir G.
et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.
Circulation. 2007;115(4):450-45817190864
Google ScholarCrossref 21.Hokanson JE. Functional variants in the lipoprotein lipase gene and risk cardiovascular disease.
Curr Opin Lipidol. 1999;10(5):393-39910554701
Google ScholarCrossref 22.Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease: a meta-analysis.
Circulation. 1999;99(22):2901-290710359734
Google ScholarCrossref 23.Benlian P, De Gennes JL, Foubert L.
et al. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene.
N Engl J Med. 1996;335(12):848-8548778602
Google ScholarCrossref 24.Manninen V, Elo MO, Frick MH.
et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
JAMA. 1988;260(5):641-6513164788
Google ScholarCrossref 25. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study.
Circulation. 2000;102(1):21-2710880410
Google ScholarCrossref 26.Robins SJ, Collins D, Wittes JT.
et al. Relation of gemfibrozil treatment and lipid levels with major coronary events.
JAMA. 2001;285(12):1585-159111268266
Google ScholarCrossref 27.Gordon DJ, Probstfield JL, Garrison RJ.
et al. High-density lipoprotein cholesterol and cardiovascular disease.
Circulation. 1989;79(1):8-152642759
Google ScholarCrossref 28.Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P.
et al. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: the Copenhagen City Heart Study.
Circulation. 2000;102(18):2197-220311056092
Google ScholarCrossref 29.Agerholm-Larsen B, Nordestgaard BG, Steffensen R.
et al. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene.
Circulation. 2000;101(16):1907-191210779455
Google ScholarCrossref 30.Hokanson JE, Cheng S, Snell-Bergeon JK.
et al. A common promoter polymorphism in the hepatic lipase gene (LIPC-480C>T) is associated with an increase in coronary calcification in type 1 diabetes.
Diabetes. 2002;51(4):1208-121311916946
Google ScholarCrossref 31.Andersen RV, Wittrup HH, Tybjaerg-Hansen A.
et al. Hepatic lipase mutations,elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study.
J Am Coll Cardiol. 2003;41(11):1972-198212798568
Google ScholarCrossref 32.Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity.
J Lipid Res. 2002;43(9):1363-137912235168
Google ScholarCrossref 33.Stampfer MJ, Krauss RM, Ma J.
et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction.
JAMA. 1996;276(11):882-8888782637
Google ScholarCrossref 34.Stensvold I, Tverdal A, Urdal P, Graff-Iversen S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women.
BMJ. 1993;307(6915):1318-13228257886
Google ScholarCrossref 35.Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study.
Arterioscler Thromb Vasc Biol. 2007;27(3):661-67017170368
Google ScholarCrossref 36.Wittrup HH, Tybjaerg-Hansen A, Abildgaard S.
et al. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease.
J Clin Invest. 1997;99(7):1606-16139120004
Google ScholarCrossref